« Return to News | R&D Trends

Ensemble, Boehringer Ingelheim collaborate on macrocycle drug candidates

Friday, November 2, 2012 10:56 AM

Ensemble Therapeutics of Cambridge, Mass., has initiated a research collaboration with Germany-based Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against several high-value pharmaceutical targets specified by Boehringer Ingelheim.

Ensemble Therapeutics is eligible to receive payments and may receive up to $186 million in success milestones in case of full commercial success of multiple drug products, including an upfront payment and research funding. In addition, Ensemble Therapeutics is eligible to receive royalties on future sales of products that arise from the collaboration. Further details of the agreement were not disclosed.

The collaboration will deploy Ensemble Therapeutics' proprietary drug discovery platforms including its Ensemblin collection of about 5 million macrocycles to discover and advance novel drug candidates against Boehringer Ingelheim's drug targets. Boehringer Ingelheim will have the exclusive right to develop and commercialize substances arising from the collaboration.

"This collaboration with Boehringer Ingelheim builds on Ensemble's business strategy to partner with leading pharmaceutical companies and further validates the wide-ranging potential of our Ensemblin drug discovery platforms while providing Ensemble with additional funding to advance our own internal pipeline," said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.